Ignite Creation Date:
2025-12-24 @ 1:58 PM
Ignite Modification Date:
2026-02-03 @ 12:47 AM
Study NCT ID:
NCT01614795
Status:
COMPLETED
Last Update Posted:
2018-12-11
First Post:
2012-06-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Childhood Rhabdomyosarcoma | View |
| None | Recurrent Childhood Soft Tissue Sarcoma | View |
| None | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | View |
| None | Recurrent Osteosarcoma | View |
| None | Rhabdomyosarcoma | View |
| None | Childhood Alveolar Soft Part Sarcoma | View |
| None | Childhood Angiosarcoma | View |
| None | Childhood Epithelioid Sarcoma | View |
| None | Childhood Fibrosarcoma | View |
| None | Childhood Gliosarcoma | View |
| None | Childhood Leiomyosarcoma | View |
| None | Childhood Liposarcoma | View |
| None | Childhood Malignant Peripheral Nerve Sheath Tumor | View |
| None | Childhood Synovial Sarcoma | View |
| None | Previously Treated Childhood Rhabdomyosarcoma | View |
Keywords: